Artecoll: a long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plastic and reconstructive surgery. [Plast Reconstr Surg] Journal article | | Title | Artecoll: a long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. | | Author(s) | Cohen SR, Holmes RE | | Institution | Division of Plastic Surgery, University of California, San Diego, USA. scohen@sdfaces.com | | Source | Plast Reconstr Surg 2004 Sep 15; 114(4):964-76; discussion 977-9. | | MeSH | Adult
Aged
Aged, 80 and over
Collagen
Comparative Study
Device Approval
Esthetics
Female
Follow-Up Studies
Humans
Injections, Subcutaneous
Male
Middle Aged
Patient Satisfaction
Polymethyl Methacrylate
Research Support, Non-U.S. Gov't
Rhytidoplasty
Treatment Outcome
| | Abstract | Artecoll, an injectable wrinkle filler composed of polymethylmethacrylate microspheres and bovine collagen, is widely available outside the United States. For domestic availability, a multicenter Investigational Device Exemption study was required by the U.S. Food and Drug Administration. This study consisted of 251 subjects at eight centers who received injections of Artecoll or the currently approved collagen dermal filler (control) in 1334 wrinkles of the glabella, nasolabial fold, radial upper lip lines, and corner-of-the-mouth lines. The treatments were randomized, and follow-up safety, efficacy, investigator success rating, and subject satisfaction rating data were collected at 1, 3, and 6 months. The safety data, measured as adverse events and immunoglobulin G serum levels, were low and similar for both groups. The efficacy data, measured by masked observers using a photographic facial fold assessment scale, demonstrated a combined significant improvement with Artecoll compared with collagen at 6 months (p < 0.001). At 6 months, the investigator success ratings and the subject satisfaction ratings for each of the four injections sites were superior for Artecoll (p < 0.001). In the Artecoll group, 12-month follow-up was obtained for 111 subjects (86.7 percent) and showed persistence of significant augmentation. Artecoll had fewer adverse events reported throughout the 12-month safety study period than the control group did in 6 months, although the difference was not statistically significant. | | Language | eng | | Pub Type(s) | Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
| | PubMed ID | 15468406 |
|
|
| |
Advertise on this site.
| | |
|
